GEM 00220
Alternative Names: GEM-00220Latest Information Update: 28 Sep 2024
Price :
$50 *
At a glance
- Originator Northern Therapeutics
- Class Mesenchymal stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Septic shock
Most Recent Events
- 28 Sep 2024 No recent reports of development identified for phase-I development in Septic-shock in Canada (IV, Infusion)
- 26 Mar 2024 Northern Therapeutics terminates a phase I trial in Septic shock in Canada (IV), considering funding decision (NCT04961658)
- 11 Aug 2021 Phase-I clinical trials in Septic shock in Canada (IV) (NCT04961658)